PulseAI announce clinical validation of Atrial Fibrillation algorithm

Belfast, Northern Ireland: Belfast-based PulseAI has announced the successful clinical validation of its AI-powered algorithm for diagnosing atrial fibrillation. The algorithm validation results will be presented at the international Computing in Cardiology conference in Tampere, Finland from the 3rd-7th of September. 

The clinical study was conducted by a team of cardiologists at Ashford and St Peter's Hospitals NHS Foundation Trust in the United Kingdom, under the direction of Dr Chris Crockford of Digital & Future Technologies. The results showed that PulseAI's AF detection algorithm had a sensitivity of 96% and a specificity of 99% in a cohort of 900 patients. 

"This is an important study that confirms the efficacy of PulseAI's AF detection algorithm in a large, diverse population," said PulseAI CEO and Founder Dr Alan Kennedy. "We are excited to share these results with the international community and look forward to continued collaboration with device manufacturers and leading clinicians to further advance our AI platform."

The PulseAI platform allows device manufacturers to easily integrate advanced AI technology into their products. It provides access to PulseAI's neural network technology, which is trained on an ever-growing proprietary database of more than 1 million patients and provides industry-leading ECG interpretation performance.

The PulseAI platform has now been validated in multiple studies and is being trialled by leading healthcare trusts and ECG device manufacturers worldwide.